atrial fibrillation ablation: my personal experience 2000-2008 helmut pürerfellner md, assoc. prof....
TRANSCRIPT
Atrial Fibrillation Ablation:Atrial Fibrillation Ablation:My personal experience 2000-2008My personal experience 2000-2008
Helmut Pürerfellner MD, Helmut Pürerfellner MD, Assoc. Prof.Assoc. Prof.
Division of CardiologyDivision of Cardiology
St.Elisabeth´s Sisters St.Elisabeth´s Sisters HospitalHospital
Academic Teaching CenterAcademic Teaching Center
Linz/AustriaLinz/Austria
Rationale for Catheter ablation of AFib:Rationale for Catheter ablation of AFib:Poor drug efficacyPoor drug efficacy
Pulmonary vein potentials (PVP)Pulmonary vein potentials (PVP)
Right atrium Left atrium
17 31
116
Superiorcaval Vein
Inferior caval vein
Fossaovalis
CoronarySinus
Pulmonary Veins
Septum
… critical zone
Sueda Sueda Ann Thorac Surg 1997Ann Thorac Surg 1997
Microreeentrant Microreeentrant circuitscircuits
HaissaguerreHaissaguerreNEJM 1998NEJM 1998
PV fociPV foci
LOMLOM
HwangHwangCirculation 2000Circulation 2000
Ablation of AFib - Ablation of AFib - TechniquesTechniques
Trigger approach:Trigger approach:
• Focal (within PV)Focal (within PV)
• Segmental ostialSegmental ostial
• Tailored approach Tailored approach
Substrate approach:Substrate approach:
• Circumferential atrialCircumferential atrial
• Additional lines (roof, mitral Additional lines (roof, mitral isthmus) isthmus)
• Substrate mapping (CAFE, Substrate mapping (CAFE, DF)DF)
• Ganglionated plexus (GP)Ganglionated plexus (GP)
PV-Angiographie (LIPV)PV-Angiographie (LIPV)
Lasso CatheterLasso Catheter
Atraumatic tip
Different loop diameters available
Micro-catheter loop featuring 10
electrodes (3F)
Deflectable Tip (B curve)
Ablation LIPVAblation LIPV
PV-DiskonnektionPV-Diskonnektion
… critical zone
Sueda Sueda Ann Thorac Surg 1997Ann Thorac Surg 1997
Microreeentrant Microreeentrant circuitscircuits
HaissaguerreHaissaguerreNEJM 1998NEJM 1998
PV fociPV foci
LOMLOM
HwangHwangCirculation 2000Circulation 2000
Ablation of AFib - Ablation of AFib - Techniques Techniques
Trigger approach:Trigger approach:
• Focal (within PV)Focal (within PV)
• Segmental ostialSegmental ostial
• Tailored approach Tailored approach
Substrate approach:Substrate approach:
• Circumferential atrialCircumferential atrial
• Additional lines (roof, mitral Additional lines (roof, mitral isthmus) isthmus)
• Substrate mapping (CAFE, Substrate mapping (CAFE, DF)DF)
• Ganglionated plexus (GP)Ganglionated plexus (GP)
PV-Antrum (CT/ICE)PV-Antrum (CT/ICE)
Wide areas circumferential ablation (WACA) Wide areas circumferential ablation (WACA) (+ left atrial lines(+ left atrial lines± ostial ablation± ostial ablation) )
SOI vs WACASOI vs WACAOral et al, Circulation 2003; 108:2355-60Oral et al, Circulation 2003; 108:2355-60
• Decrease in local atrial Decrease in local atrial electrogram amplitude electrogram amplitude >50% or amplitude <0,1mV >50% or amplitude <0,1mV (voltage abatement)(voltage abatement)
• Additional ablation within Additional ablation within circumferential lines in 32%circumferential lines in 32%
SOI vs WACA SOI vs WACA Oral et al, Circulation 2003; 108:2355-60Oral et al, Circulation 2003; 108:2355-60
Success rates (extraostial)Success rates (extraostial)
Complication rates (extraostial)Complication rates (extraostial)
AFib-Ablation Elisabethinen Hospital Linz AFib-Ablation Elisabethinen Hospital Linz 2001-20052001-2005
• Period 01/2001 – 05/2005Period 01/2001 – 05/2005
• N=200 Pat.N=200 Pat.
• Age 53Age 53±10 a ±10 a
• 82%m, 18%f82%m, 18%f
Arrhythmia Arrhythmia
• Paroxysmal: n=162 (81%)Paroxysmal: n=162 (81%)
• Persistent: n=32 (16%)Persistent: n=32 (16%)
• Permanent: n=5 (2,5%)Permanent: n=5 (2,5%)
ProceduresProcedures
• N=276N=276
• Procedures: Procedures:
1.1. Lasso (segmental ostial)Lasso (segmental ostial)
2.2. Pappone (circumferential)Pappone (circumferential)
3.3. Combi (circumferentiell Combi (circumferentiell + ostial)+ ostial)
4.4. Mixed Mixed
Follow upFollow up
• Fu after 1 month (clinical examination, 24h-Holter-Fu after 1 month (clinical examination, 24h-Holter-EKG, QOL) EKG, QOL)
• In hospital Fu at 3, 6 und 24 months (clinical In hospital Fu at 3, 6 und 24 months (clinical examination, Holter/Monitor, Echo, stress test, examination, Holter/Monitor, Echo, stress test, Spiral-CT, TEE, QOL; Lung scan and MRI as Spiral-CT, TEE, QOL; Lung scan and MRI as needed)needed)
Classification of successClassification of success
• Complete : 0 recurrences, 0 drugComplete : 0 recurrences, 0 drug
• Partial: Partial: 0 recurrences, + drug 0 recurrences, + drug
• failure:failure: + recurrences, + drug + recurrences, + drug
• Clinical response: complete + partial successClinical response: complete + partial success
Success/patient Success/patient
AFib paroxysmalAFib paroxysmal
JICE 2007
Study designStudy design
• 40 consecutive patients (40 consecutive patients (56.4 ± 9.6 y; 36 male)56.4 ± 9.6 y; 36 male)
Multislice computed tomography imagingMultislice computed tomography imaging
• 16-slice MSCT16-slice MSCT
• Non ionic contrast agentNon ionic contrast agent
• Caudocranial scanningCaudocranial scanning
• Exspiratory breath-holdExspiratory breath-hold
• Barium contrast (esophagus)Barium contrast (esophagus)
Electroanatomic mappingElectroanatomic mapping
• 4-mm irregated tip 4-mm irregated tip quadripolar catheterquadripolar catheter
• Contact mapping of Contact mapping of LA and PVsLA and PVs
• EAM and MSCT EAM and MSCT displayed next to displayed next to each other each other
Allignment of MSCT and EAMAllignment of MSCT and EAM
• Landmark registrationLandmark registration
• Visual allignmentVisual allignment
• Surface registrationSurface registration
AF ablation procedureAF ablation procedure
• Circumferential Circumferential approachapproach
(Pappone C et al., (Pappone C et al., Circulation 2000;102(21):2562-4))
• PV-IsolationPV-Isolation
(Haissaguerre M et al., (Haissaguerre M et al., N Engl J Med 1998;339:659–65))
• Additional linesAdditional lines
Accuracy Accuracy (position error)(position error)
POSTPRE
4
3
2
1
0
Mean = 1.6mm
Mean = 2.3mm
> No difference between SR and AF.
> Independent of number of points.
StudiesStudies
(J Cardiovasc Electrophysiol, Vol. 17, pp. 341-348, April 2006)
Position error: 2.3 ± 0.4 mm
(Heart Rhythm 2005;2:1076 –1081)
Position error: 2.1 ± 0.2 mm
Our results:
1,6 ± 1,2 mm (pre)
2,3 ± 1,8 mm (post)
ConclusionConclusion
• Integration of MSCT scanning into 3D EAM is Integration of MSCT scanning into 3D EAM is feasible and accurate.feasible and accurate.
• Cardiac rhythm during procedure has no influence Cardiac rhythm during procedure has no influence on the precision of fusion.on the precision of fusion.
• Matching accuracy decreases after multiple Matching accuracy decreases after multiple ablations.ablations.
• Combining EAM and imaging methods might Combining EAM and imaging methods might provide easier, faster and more reliable ablation provide easier, faster and more reliable ablation procedures in AF.procedures in AF.
INTRODUCTIONINTRODUCTION
Does MSCT integration into 3D EAM …Does MSCT integration into 3D EAM …
• ……lower complication rate of RF ablation?lower complication rate of RF ablation?
• ……improve of clinical outcome?improve of clinical outcome?
• ……enhance procedural efficacy?enhance procedural efficacy?
– Procedural durationProcedural duration
– Radiation timesRadiation times
METHODSMETHODS
• 161 consecutive patients (134 male)161 consecutive patients (134 male)
• Mean age 55.5 ± 9.5 yMean age 55.5 ± 9.5 y
• Multi-drug-resistant AF (2.4±1.1 failed AAD)Multi-drug-resistant AF (2.4±1.1 failed AAD)
• Serial MSCT before and 3 months after ablationSerial MSCT before and 3 months after ablation
• 24-hour Holter and patients questionnaire at 3 24-hour Holter and patients questionnaire at 3 months after proceduremonths after procedure
CartoXPCartoXPTMTM vs. CartoMerge vs. CartoMergeTMTM
CARTO XP:
79 pts.
CARTO Merge:
82 pts.
BASELINE CHARACTERISTICSBASELINE CHARACTERISTICS
RESULTS - SAFETYRESULTS - SAFETY
ZeroZero PV stenosis in the PV stenosis in the CartoMERGE group CartoMERGE group
versusversus
FiveFive in the conventional in the conventional group (p=0.021).group (p=0.021).
Severe adverse events in Severe adverse events in total considerably reduced total considerably reduced (8 vs. 2; p=0.043). (8 vs. 2; p=0.043).
Procedure-related Complications
0
1
2
3
4
5
6
7
8
9
XP MergeProcedure Type
Num
ber o
f Pat
ient
s Phrenic Nerve Injury
Pericardial Effusion
TIA/Cerebral Infarction
PV-Stenosis
RESULTS - OUTCOMERESULTS - OUTCOME
failure full success success on drugs
Outcome nach 3 Monaten
0
10
20
30
40
50
60
Pe
rce
nt
Verfahrensart
XP
Merge
Outcome at 3 months
Overall success afterOverall success after
3 months:3 months:
- CARTO XP 71%- CARTO XP 71%
- CARTOMerge 87.5%- CARTOMerge 87.5%
p = 0.019.p = 0.019.
Martinek et al, PACE 2007
RESULTS - EFFICACYRESULTS - EFFICACY
CONCLUSIONCONCLUSION
MSCT image integration into 3D EAM …MSCT image integration into 3D EAM …
… … significantly improves safety …significantly improves safety …
… … significantly enhances success …significantly enhances success …
of WACA with confirmed PV isolation and of WACA with confirmed PV isolation and additional lines.additional lines.
Image IntegrationImage Integration
AFib Ablation Lesion SetsAFib Ablation Lesion Sets
Are you sure you know what you are Are you sure you know what you are doing ?doing ?
Journal of Cardiovasc Electrophysiol 2007Journal of Cardiovasc Electrophysiol 2007
Catheter Ablation of AF 2008 – Catheter Ablation of AF 2008 – Open issuesOpen issues
• AF as first-line treatment (RAAFT, CACAF, APAF)AF as first-line treatment (RAAFT, CACAF, APAF)
• Persistent/long standing persistent AF („chronic AF“)Persistent/long standing persistent AF („chronic AF“)
• Energy Source/Catheter designEnergy Source/Catheter design
• Remote navigationRemote navigation
• Vs AAA (CABANA), vs A+P (PABA-CHF)Vs AAA (CABANA), vs A+P (PABA-CHF)
• AF and CHFAF and CHF
• Mortality (CASTLE-AF)Mortality (CASTLE-AF)
• Cost-effectivenessCost-effectiveness